Stockscreener 앱 받기
5.35
7.21%
0.36
시장 영업 전:
5.35
전일 마감가:
$4.99
열려 있는:
$5.07
하루 거래량:
155.56K
Relative Volume:
0.78
시가총액:
$33.11M
수익:
$4.71M
순이익/손실:
$-90.32M
주가수익비율:
-0.6147
EPS:
-8.7032
순현금흐름:
$-85.19M
1주 성능:
+3.68%
1개월 성능:
-6.30%
6개월 성능:
-49.67%
1년 성능:
-28.95%
1일 변동 폭
$5.07
$5.73
1주일 범위
$4.91
$5.73
52주 변동 폭
$4.80
$13.69
Aligos Therapeutics Inc Stock (ALGS) Company Profile
명칭
Aligos Therapeutics Inc
전화
(800) 466-6059
주소
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
5.35 | 31.62M | 4.71M | -90.32M | -85.19M | -8.7032 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-19 | 재개 | Jefferies | Buy |
| 2025-08-18 | 재개 | H.C. Wainwright | Buy |
| 2024-08-19 | 개시 | H.C. Wainwright | Buy |
| 2023-01-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-01-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-01-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-09 | 개시 | SVB Leerink | Outperform |
| 2021-05-17 | 재개 | Piper Sandler | Overweight |
| 2020-11-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-10 | 개시 | JP Morgan | Overweight |
| 2020-11-10 | 개시 | Jefferies | Buy |
| 2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Aligos Therapeutics Inc 주식(ALGS)의 최신 뉴스
Aligos Therapeutics (ALGS) Slides 8% – Support Test on the Horizon?Factor Rotation - newsline.com
Aligos Therapeutics Inc (ALGS) Stock Price, Quote, News & History - Benzinga
Lake Street Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Aligos Therapeutics (ALGS) Gets a Buy from Cantor Fitzgerald - The Globe and Mail
How (ALGS) Movements Inform Risk Allocation Models - Stock Traders Daily
Cantor Fitzgerald reiterates Aligos stock Overweight on HBV data By Investing.com - Investing.com Nigeria
Aligos’ ALG-215007 candidate ASO for HDV infection - BioWorld News
Cantor Fitzgerald reiterates Aligos stock Overweight on HBV data - Investing.com
Lake Street Initiates Aligos Therapeutics(ALGS.US) With Buy Rating, Announces Target Price $45 - Moomoo
ALGS Initiated Coverage by Lake Street -- Price Target Announced at $45 - GuruFocus
Aligos Therapeutics stock initiated at Buy by Lake Street on HBV drug potential - Investing.com South Africa
Aligos Therapeutics (ALGS) Showcases Promising Data at EASL Cong - GuruFocus
Hepatitis B data: 40% on Aligos drug reach HBsAg level used for cure regimens - Stock Titan
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 - Investing News Network
Aligos Therapeutics Presents Positive Phase 1 Data for Pevifoscorvir Sodium at EASL Congress 2026, Suggesting Reduced cccDNA Reservoir in Chronic HBV Patients - Quiver Quantitative
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 - GlobeNewswire Inc.
ALGS Q1 2026 Earnings: Narrower-Than-Expected Loss as Aligos Therapeutics Advances PipelineRevenue Estimate Trend - newsline.com
Cantor Fitzgerald Initiates Aligos Therapeutics(ALGS.US) With Buy Rating, Announces Target Price $20 - Moomoo
ALGS Initiated Coverage by Cantor Fitzgerald -- Rating Set to Ov - GuruFocus
ALGS News | ALIGOS THERAPEUTICS INC (NASDAQ:ALGS) - ChartMill
Lawrence M. Blatt discloses 5.1% stake in Aligos Therapeutics (ALGS) - Stock Titan
Aligos (ALGS) Delivers Q1 2026 Beat — EPS $-2.21 vs $-2.27 ExpectedSocial Trade Signals - Newser
Woodline Partners reports 4.4% stake in Aligos Therapeutics (NASDAQ: ALGS) - Stock Titan
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 - The Manila Times
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at EASL Congress 2026 - Quiver Quantitative
Liver disease drug data: Aligos secures 10 EASL 2026 slots - Stock Titan
TradingKey - TradingKey
What you need to know before buying Aligos (ALGS) (Investor Concern) 2026-05-08Crowd Consensus Signals - newser.com
The operating leverage hidden in Aligos (ALGS) results | Q1 2026: EPS Exceeds ExpectationsTarget Revision - Newser
Aligos Therapeutics (NASDAQ:ALGS) Surges After Hours on Q1 Earnings Beat - ChartMill
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - Investing News Network
China HBV license adds cash as Aligos (NASDAQ: ALGS) faces going‑concern risk - Stock Titan
Aligos lands FDA Fast Track and a $25M China deal for HBV drug - Stock Titan
Earnings Preview: ALGS to Report Financial Results Post-market on May 07 - Moomoo
How Aligos Therapeutics Inc. (ALGS) Affects Rotational Strategy Timing - Stock Traders Daily
Aligos Therapeutics Inc expected to post a loss of $2.22 a shareEarnings Preview - TradingView
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026 - The Manila Times
Biotech Aligos will post first-quarter results after markets close May 7 - Stock Titan
[ARS] Aligos Therapeutics, Inc. SEC Filing - Stock Titan
Aligos Therapeutics says China pact puts HBV drug in focus amid trial updates - MSN
Aligos Therapeutics (Nasdaq: ALGS) details ESPP, auditor and pay votes - Stock Titan
Aligos’ licensing deal in China broadens trial scope, secures immediate $25m - MLex
Is Aligos (ALGS) overbought or oversold? (Drifts Higher) 2026-04-27Retail Flow - Newser
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Aligos Therapeutics Inc (ALGS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):